CTOs on the Move

Counsyl

www.counsyl.com

 
Counsyl is a DNA testing and genetic counseling service that offers genetic screening for men, women and their children. Our philosophy is simple - focus on diseases where advanced knowledge makes a difference in health outcomes, whether it`s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead. Counsyl has screened over 750,000 patients and served over 10,000 health professionals in its modern clinical laboratory. From the purely mechanical to profoundly human, Counsyl strives to make genetic screening truly accessible to everyone. The team consists of world class engineers, scientists and clinical experts as well as a ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.counsyl.com
  • 180 Kimball Way
    South San Francisco, CA USA 94080
  • Phone: 888.268.6795

Executives

Name Title Contact Details

Funding

Counsyl raised $80M on 11/06/2017

Similar Companies

Banyan Hypnosis Ctr-Training

Banyan Hypnosis Ctr-Training is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PACS

Providence Administrative Consulting Services (PACS) provides administrative support services that elevate skilled nursing facilities, empowering and equipping local leadership teams to deliver excellent care and make positive contributions to their co...

Optras Systems Pvt.

Optras Systems Pvt. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virginia Mason Medical Center

Virginia Mason Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Seattle, WA. To find more information about Virginia Mason Medical Center, please visit www.vmmc.org

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.